These indoloquinoxaline derivatives produced multitargeted activities against Alzheimer’s disease, such as cholinesterase inhibition, self-induced Aβ aggregation inhibition, and antioxidant activity. This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.